Suppr超能文献

对病理学队列中的神经退行性疾病进行遗传分析。

Genetic analysis of neurodegenerative diseases in a pathology cohort.

机构信息

Neurodegenerative Diseases Research Unit, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.

Department of Pathology (Neuropathology), Johns Hopkins University School of Medicine, Baltimore, MD, USA.

出版信息

Neurobiol Aging. 2019 Apr;76:214.e1-214.e9. doi: 10.1016/j.neurobiolaging.2018.11.007. Epub 2018 Nov 17.

Abstract

Molecular genetic research provides unprecedented opportunities to examine genotype-phenotype correlations underlying complex syndromes. To investigate pathogenic mutations and genotype-phenotype relationships in diverse neurodegenerative conditions, we performed a rare variant analysis of damaging mutations in autopsy-confirmed neurodegenerative cases from the Johns Hopkins Brain Resource Center (n = 1243 patients). We used NeuroChip genotyping and C9orf72 hexanucleotide repeat analysis to rapidly screen our cohort for disease-causing mutations. In total, we identified 42 individuals who carried a pathogenic mutation in LRRK2, GBA, APP, PSEN1, MAPT, GRN, C9orf72, SETX, SPAST, or CSF1R, and we provide a comprehensive description of the diverse clinicopathological features of these well-characterized cases. Our study highlights the utility of high-throughput genetic screening arrays to establish a molecular diagnosis in individuals with complex neurodegenerative syndromes, to broaden disease phenotypes and to provide insights into unexpected disease associations.

摘要

分子遗传学研究为研究复杂综合征的基因型-表型相关性提供了前所未有的机会。为了研究不同神经退行性疾病中的致病突变和基因型-表型关系,我们对约翰霍普金斯脑资源中心(Johns Hopkins Brain Resource Center)经过尸检证实的神经退行性病例(n=1243 例)中的破坏性突变进行了罕见变异分析。我们使用 NeuroChip 基因分型和 C9orf72 六核苷酸重复分析快速筛查我们的队列中是否存在致病突变。总共,我们确定了 42 名个体携带 LRRK2、GBA、APP、PSEN1、MAPT、GRN、C9orf72、SETX、SPAST 或 CSF1R 的致病性突变,我们提供了这些特征明确病例的广泛临床病理特征的全面描述。我们的研究强调了高通量遗传筛选阵列在具有复杂神经退行性综合征的个体中建立分子诊断的效用,以拓宽疾病表型并深入了解意外的疾病关联。

相似文献

1
Genetic analysis of neurodegenerative diseases in a pathology cohort.
Neurobiol Aging. 2019 Apr;76:214.e1-214.e9. doi: 10.1016/j.neurobiolaging.2018.11.007. Epub 2018 Nov 17.
3
C9ORF72 repeat expansions in cases with previously identified pathogenic mutations.
Neurology. 2013 Oct 8;81(15):1332-41. doi: 10.1212/WNL.0b013e3182a8250c. Epub 2013 Sep 11.
4
Genetic Features of MAPT, GRN, C9orf72 and CHCHD10 Gene Mutations in Chinese Patients with Frontotemporal Dementia.
Curr Alzheimer Res. 2017;14(10):1102-1108. doi: 10.2174/1567205014666170426105713.
5
NeuroChip, an updated version of the NeuroX genotyping platform to rapidly screen for variants associated with neurological diseases.
Neurobiol Aging. 2017 Sep;57:247.e9-247.e13. doi: 10.1016/j.neurobiolaging.2017.05.009. Epub 2017 May 17.
6
Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study.
Lancet Neurol. 2020 Feb;19(2):145-156. doi: 10.1016/S1474-4422(19)30394-1. Epub 2019 Dec 3.
7
Genetic screening in early-onset dementia patients with unclear phenotype: relevance for clinical diagnosis.
Neurobiol Aging. 2018 Sep;69:292.e7-292.e14. doi: 10.1016/j.neurobiolaging.2018.04.015. Epub 2018 May 9.
10
Clinical profiles associated with LRRK2 and GBA mutations in Brazilians with Parkinson's disease.
J Neurol Sci. 2017 Oct 15;381:160-164. doi: 10.1016/j.jns.2017.08.3249. Epub 2017 Aug 24.

引用本文的文献

1
Accumulation of LRRK2-associated phospho-Rab12 degenerative lysosomes in tauopathies.
bioRxiv. 2025 Jun 9:2025.06.06.658328. doi: 10.1101/2025.06.06.658328.
2
LRRK2-mediated mitochondrial dysfunction in Parkinson's disease.
Biochem J. 2025 May 28;482(11):BCJ20253062. doi: 10.1042/BCJ20253062.
3
Abundant non-inclusion α-synuclein pathology in Lewy body-negative LRRK2-mutant cases.
Acta Neuropathol. 2025 May 2;149(1):41. doi: 10.1007/s00401-025-02871-w.
4
An Update on Neuroaging on Earth and in Spaceflight.
Int J Mol Sci. 2025 Feb 18;26(4):1738. doi: 10.3390/ijms26041738.
5
Updated MDSGene review on the clinical and genetic spectrum of LRRK2 variants in Parkinson´s disease.
NPJ Parkinsons Dis. 2025 Feb 17;11(1):30. doi: 10.1038/s41531-025-00881-9.
6
G9a an Epigenetic Therapeutic Strategy for Neurodegenerative Conditions: From Target Discovery to Clinical Trials.
Med Res Rev. 2025 May;45(3):985-1015. doi: 10.1002/med.22096. Epub 2025 Jan 6.
7
-Related Disorder: Prevalence of Variants and Their Clinical Significance in the UK Population.
Neurol Genet. 2024 Jul 16;10(4):e200179. doi: 10.1212/NXG.0000000000200179. eCollection 2024 Aug.
8
LRRK2 kinase inhibition reverses G2019S mutation-dependent effects on tau pathology progression.
Transl Neurodegener. 2024 Mar 4;13(1):13. doi: 10.1186/s40035-024-00403-2.
9
Reappraisal of the Concept of Accelerated Aging in Neurodegeneration and Beyond.
Cells. 2023 Oct 14;12(20):2451. doi: 10.3390/cells12202451.
10
Genome-wide structural variant analysis identifies risk loci for non-Alzheimer's dementias.
Cell Genom. 2023 May 4;3(6):100316. doi: 10.1016/j.xgen.2023.100316. eCollection 2023 Jun 14.

本文引用的文献

2
NeuroChip, an updated version of the NeuroX genotyping platform to rapidly screen for variants associated with neurological diseases.
Neurobiol Aging. 2017 Sep;57:247.e9-247.e13. doi: 10.1016/j.neurobiolaging.2017.05.009. Epub 2017 May 17.
3
M-CAP eliminates a majority of variants of uncertain significance in clinical exomes at high sensitivity.
Nat Genet. 2016 Dec;48(12):1581-1586. doi: 10.1038/ng.3703. Epub 2016 Oct 24.
4
Study of LRRK2 variation in tauopathy: Progressive supranuclear palsy and corticobasal degeneration.
Mov Disord. 2017 Jan;32(1):115-123. doi: 10.1002/mds.26815. Epub 2016 Oct 6.
5
Analysis of protein-coding genetic variation in 60,706 humans.
Nature. 2016 Aug 18;536(7616):285-91. doi: 10.1038/nature19057.
6
Novel LRRK2 mutations in Parkinsonism.
Parkinsonism Relat Disord. 2015 Sep;21(9):1119-21. doi: 10.1016/j.parkreldis.2015.07.011. Epub 2015 Jul 18.
8
Second-generation PLINK: rising to the challenge of larger and richer datasets.
Gigascience. 2015 Feb 25;4:7. doi: 10.1186/s13742-015-0047-8. eCollection 2015.
9
A general framework for estimating the relative pathogenicity of human genetic variants.
Nat Genet. 2014 Mar;46(3):310-5. doi: 10.1038/ng.2892. Epub 2014 Feb 2.
10
Alzheimer disease in the United States (2010-2050) estimated using the 2010 census.
Neurology. 2013 May 7;80(19):1778-83. doi: 10.1212/WNL.0b013e31828726f5. Epub 2013 Feb 6.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验